• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Novo vs. KBP: How a $1.3B deal turned into an international legal fight

Clinical Data

heart over ekg
Biotech

Ventyx's CV drug rapidly reduces cardio risk biomarker

Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week.
James Waldron Oct 23, 2025 9:45am
Cytomegalovirus CMV herpes herpesvirus virus

Moderna scraps congenital virus program after vax fails ph. 3

Oct 22, 2025 5:15pm
Wall Street IPO initial public offering markets shares stock

Arcturus' stock halves on cystic fibrosis readout

Oct 22, 2025 1:01pm
brain

Alector halves staff after GSK-partnered antibody fails in ph. 3

Oct 22, 2025 11:23am
On target clinical trial success bullseye score

Sanofi's $1.7B bet beats CSL's Zemaira in phase 2 face-off

Oct 22, 2025 10:35am
Make a delay and accumulation of outstanding tasks Full stop

Terns mothballs obesity program after phase 2 data fall short

Oct 22, 2025 7:15am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings